Page last updated: 2024-08-17

quinoxalines and vanoxerine

quinoxalines has been researched along with vanoxerine in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goldstein, DS; Kopin, IJ; Pacak, K; Yadid, G1
Koob, GF; Parsons, LH; Weiss, F1
Hashim, A; Lajtha, A; Sershen, H1
Matsubara, K; Ohtaki, K; Shimizu, K; Shiono, H1
Bryan-Lluka, LJ; Paczkowski, FA; Papacostas, MH; Wanstall, JC1

Other Studies

5 other study(ies) available for quinoxalines and vanoxerine

ArticleYear
Endogenous serotonin stimulates striatal dopamine release in conscious rats.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 270, Issue:3

    Topics: 5,7-Dihydroxytryptamine; Alanine; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Male; Microdialysis; Perfusion; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists

1994
Serotonin1b receptor stimulation enhances dopamine-mediated reinforcement.
    Psychopharmacology, 1996, Volume: 128, Issue:2

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Cocaine; Conditioning, Operant; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Narcotics; Piperazines; Quinoxalines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Self Administration; Serotonin Receptor Agonists

1996
Serotonin-mediated striatal dopamine release involves the dopamine uptake site and the serotonin receptor.
    Brain research bulletin, 2000, Volume: 53, Issue:3

    Topics: Animals; Bicuculline; Cocaine; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; GABA Antagonists; Ketanserin; Male; Methiothepin; Mice; Mice, Inbred C57BL; Oxymetazoline; Piperazines; Quinoxalines; Quipazine; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists

2000
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.
    Neuroscience research, 2003, Volume: 46, Issue:4

    Topics: 1-Methyl-4-phenylpyridinium; Analysis of Variance; Animals; Animals, Newborn; Azepines; Cabergoline; Caspases; Cell Count; Cycloheximide; Dizocilpine Maleate; Dopamine Agonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ergolines; Excitatory Amino Acid Antagonists; Herbicides; Immunohistochemistry; Mesencephalon; NADPH Dehydrogenase; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Organ Culture Techniques; Paraquat; Piperazines; Protein Synthesis Inhibitors; Quinoxalines; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase

2003
Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT).
    British journal of pharmacology, 2004, Volume: 143, Issue:1

    Topics: Animals; Biological Transport; Catalase; Chlorocebus aethiops; COS Cells; Culture Media; Cysteine; DNA, Complementary; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Guanylate Cyclase; Humans; Hydroxocobalamin; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Nerve Tissue Proteins; Nitric Oxide Donors; Nitro Compounds; Oxadiazoles; Peroxynitrous Acid; Piperazines; Quinoxalines; Serotonin; Serotonin Plasma Membrane Transport Proteins; Superoxide Dismutase; Transfection

2004